Volume Alert - XOMA 4.47 Xoma Ltd $XOMA Hit a high
Post# of 74
Posted On: 11/20/2014 2:07:09 PM
Volume Alert - XOMA 4.47 Xoma Ltd $XOMA Hit a high today of 4.49 Closing the day 10:30 at 4.47 +0.36 +8.76% With a day low of 4.17 and a total volume of 1,085,735.
XOMA Recent Posts: http://investorshangout.com/Xoma-Ltd-XOMA-55936/
XOMA Xoma Ltd Recent Headline News
XOMA Up 8.4%, Shares Break Through Resistance (XOMA)
Comtex SmarTrend(R) - 2 hrs 57 mins ago
XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 8.4% to $4.46 on 1.2x average daily volume. Thus far today, XOMA has traded 1.4 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.0%) and outperformed the S&P 500 (8.5% to the S&P's 0.1%) during today's trading.
XOMA: 4.55 (+0.44)
Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
at The Street - Thu Nov 20, 9:02AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
XOMA: 4.55 (+0.44)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 10.73 (+0.76), GERN: 3.22 (+0.11), TKMR: 16.06 (-0.06), GALE: 1.86 (+0.05), XOMA: 4.55 (+0.44), EXEL: 1.75 (+0.05)
XOMA's (XOMA) Presents at Credit Suisse 2014 Healthcare Conference Call (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 10:49PM CST
XOMA: 4.55 (+0.44)
XOMA to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 1:16PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The details are as follows:
XOMA: 4.55 (+0.44)
Downgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Mon Nov 10, 8:05AM CST
XOMA (NASDAQ:XOMA) was downgraded from Buy to Neutral at Ladenburg today. The stock closed yesterday at $3.81 on volume of 2.8 million shares, above average daily volume of 1.2 million. There is potential upside of 136.2% for shares of XOMA based on a current price of $3.81 and an average consensus analyst price target of $9.00. XOMA shares should first meet resistance at the 50-day moving average (MA) of $4.28 and find additional resistance at the 200-day MA of $4.90.
XOMA: 4.55 (+0.44)
Stock to Watch: XOMA Down 7.4% (XOMA)
Comtex SmarTrend(R) - Fri Nov 07, 10:11AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 7.4% to $3.82 on 1.1x average daily volume. XOMA has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-7.4% to the Dow's -0.0%) and underperformed the S&P 500 (-7.4% to the S&P's 0.1%) during today's trading.
XOMA: 4.55 (+0.44)
XOMA's (XOMA) CEO John Varian on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:29PM CST
XOMA: 4.55 (+0.44)
Xoma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:51PM CST
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Thursday reported a loss of $14.4 million in its third quarter.
XOMA: 4.55 (+0.44)
XOMA (XOMA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
XOMA: 4.55 (+0.44)
XOMA EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:18PM CST
XOMA: 4.55 (+0.44)
XOMA Highlights Recent Achievements and Reports Financial Results for the Third Quarter of 2014
GlobeNewswire - Thu Nov 06, 3:01PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and financial results for the quarter ended September 30, 2014.
XOMA: 4.55 (+0.44)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 108.96 (-0.12), ENDP: 69.42 (+0.41), AUXL: 33.16 (+0.13), SHPG: 210.97 (+3.39), DNDN: 0.13 (-0.02), SNSS: 2.05 (-0.08), ABBV: 65.37 (-0.13), SNY: 47.00 (-1.09), MNKD: 6.19 (-0.15), XOMA: 4.55 (+0.44)
Should You Buy XOMA Corporation (XOMA) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:45AM CST
XOMA could beat earnings estimates this season backed by favorable earnings estimate revision activity
XOMA: 4.55 (+0.44)
Xoma PG trial open for enrollment
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:05PM CST
XOMA: 4.55 (+0.44)
XOMA Initiates Pivotal Phase 3 Gevokizumab Study in Patients With Pyoderma Gangrenosum
GlobeNewswire - Tue Nov 04, 8:01AM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its pivotal Phase 3 gevokizumab study in patients with active pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulcers caused by this rare and debilitating disease. The FDA granted orphan drug designation to gevokizumab for PG in February 2014.
XOMA: 4.55 (+0.44)
Looking For My Next Triple In Biotech
Bret Jensen - at Seeking Alpha - Fri Oct 31, 12:26PM CDT
PGNX: 6.39 (+0.02), AVNR: 13.86 (+0.29), XOMA: 4.55 (+0.44)
Xoma reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:49PM CDT
XOMA: 4.55 (+0.44)
XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6
GlobeNewswire - Mon Oct 27, 1:49PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, November 6, 2014, at 4:30 p.m. Eastern time to discuss third quarter 2014 financial results and provide an update on gevokizumab's global clinical programs.
XOMA: 4.55 (+0.44)
XOMA Recent Posts: http://investorshangout.com/Xoma-Ltd-XOMA-55936/
XOMA Xoma Ltd Recent Headline News
XOMA Up 8.4%, Shares Break Through Resistance (XOMA)
Comtex SmarTrend(R) - 2 hrs 57 mins ago
XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 8.4% to $4.46 on 1.2x average daily volume. Thus far today, XOMA has traded 1.4 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.0%) and outperformed the S&P 500 (8.5% to the S&P's 0.1%) during today's trading.
XOMA: 4.55 (+0.44)
Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
at The Street - Thu Nov 20, 9:02AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
XOMA: 4.55 (+0.44)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 10.73 (+0.76), GERN: 3.22 (+0.11), TKMR: 16.06 (-0.06), GALE: 1.86 (+0.05), XOMA: 4.55 (+0.44), EXEL: 1.75 (+0.05)
XOMA's (XOMA) Presents at Credit Suisse 2014 Healthcare Conference Call (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 10:49PM CST
XOMA: 4.55 (+0.44)
XOMA to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 1:16PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The details are as follows:
XOMA: 4.55 (+0.44)
Downgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Mon Nov 10, 8:05AM CST
XOMA (NASDAQ:XOMA) was downgraded from Buy to Neutral at Ladenburg today. The stock closed yesterday at $3.81 on volume of 2.8 million shares, above average daily volume of 1.2 million. There is potential upside of 136.2% for shares of XOMA based on a current price of $3.81 and an average consensus analyst price target of $9.00. XOMA shares should first meet resistance at the 50-day moving average (MA) of $4.28 and find additional resistance at the 200-day MA of $4.90.
XOMA: 4.55 (+0.44)
Stock to Watch: XOMA Down 7.4% (XOMA)
Comtex SmarTrend(R) - Fri Nov 07, 10:11AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 7.4% to $3.82 on 1.1x average daily volume. XOMA has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-7.4% to the Dow's -0.0%) and underperformed the S&P 500 (-7.4% to the S&P's 0.1%) during today's trading.
XOMA: 4.55 (+0.44)
XOMA's (XOMA) CEO John Varian on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:29PM CST
XOMA: 4.55 (+0.44)
Xoma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:51PM CST
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Thursday reported a loss of $14.4 million in its third quarter.
XOMA: 4.55 (+0.44)
XOMA (XOMA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
XOMA: 4.55 (+0.44)
XOMA EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:18PM CST
XOMA: 4.55 (+0.44)
XOMA Highlights Recent Achievements and Reports Financial Results for the Third Quarter of 2014
GlobeNewswire - Thu Nov 06, 3:01PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and financial results for the quarter ended September 30, 2014.
XOMA: 4.55 (+0.44)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 108.96 (-0.12), ENDP: 69.42 (+0.41), AUXL: 33.16 (+0.13), SHPG: 210.97 (+3.39), DNDN: 0.13 (-0.02), SNSS: 2.05 (-0.08), ABBV: 65.37 (-0.13), SNY: 47.00 (-1.09), MNKD: 6.19 (-0.15), XOMA: 4.55 (+0.44)
Should You Buy XOMA Corporation (XOMA) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:45AM CST
XOMA could beat earnings estimates this season backed by favorable earnings estimate revision activity
XOMA: 4.55 (+0.44)
Xoma PG trial open for enrollment
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:05PM CST
XOMA: 4.55 (+0.44)
XOMA Initiates Pivotal Phase 3 Gevokizumab Study in Patients With Pyoderma Gangrenosum
GlobeNewswire - Tue Nov 04, 8:01AM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its pivotal Phase 3 gevokizumab study in patients with active pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulcers caused by this rare and debilitating disease. The FDA granted orphan drug designation to gevokizumab for PG in February 2014.
XOMA: 4.55 (+0.44)
Looking For My Next Triple In Biotech
Bret Jensen - at Seeking Alpha - Fri Oct 31, 12:26PM CDT
PGNX: 6.39 (+0.02), AVNR: 13.86 (+0.29), XOMA: 4.55 (+0.44)
Xoma reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:49PM CDT
XOMA: 4.55 (+0.44)
XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6
GlobeNewswire - Mon Oct 27, 1:49PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, November 6, 2014, at 4:30 p.m. Eastern time to discuss third quarter 2014 financial results and provide an update on gevokizumab's global clinical programs.
XOMA: 4.55 (+0.44)
(0)
(0)